Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2007-08-21
2007-08-21
Gambel, Phillip (Department: 1644)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387100, C530S387900, C530S388100, C530S388200, C530S388220, C530S388700, C530S388730, C424S130100, C424S137100, C424S139100, C424S141100, C424S143100, C424S144100, C424S152100, C424S153100, C424S154100, C424S172100, C424S173100, C435S325000, C435S326000, C435S331000, C435S332000, C435S034000, C435S343000, C435S343100, C435S343200, C435S346000
Reexamination Certificate
active
09509283
ABSTRACT:
A polypeptide (8F4 molecule) with a T-cell costimulating biological activity is disclosed, as well as monoclonal antibodies against said 8F4 molecule and hybridoma cells which produce the monoclonal antibodies, the use as medicaments of substances which inhibit the biological activity of the disclosed 8F4 polypeptide, in particular monoclonal antibodies, natural or synthetic ligands, agonists or antagonists, in particular for preventing or treating diseases which involve the immune system, the use of said 8F4 molecule or cells containing said 8F4 molecule as medicaments, in particular for preventing or treating diseases which involve the immune system, and the use of substances which specifically recognize the disclosed polypeptide, in particular monoclonal antibodies, natural or synthetic ligands, agonists or antagonists, for diagnosing diseases which involve the immune system.
REFERENCES:
patent: 2002/0115831 (2002-08-01), Tamatani et al.
patent: 2002/0151685 (2002-10-01), Tamatani et al.
patent: 2002/0156242 (2002-10-01), Tamatani et al.
patent: 984 023 (1998-02-01), None
patent: WO89/10398 (1989-11-01), None
patent: WO90/04180 (1990-04-01), None
patent: WO98/38216 (1998-09-01), None
patent: WO99/15553 (1999-04-01), None
CRL 8001 ATCC Cell Lines and Hybridomas, p. 393, 8th edition, 1994 American Type Culture Collection catalog.
Regenmortel METHODS: A companion to Methods in Enzymology 1996; 9:465-472.
Barbey et al., “Del Cell Line: A “Malignant Histiocytosis” CD30+ t(5;6)(q35;p21) Cell Line,”Int. J. Cancer45:546-553 (1990).
Chambers and Allison, “Co-Stimulation in T Cell Reponses,”Current Opinion in Immunology9:396-404 (1997).
Chirgwin et al., “Isolation of Biologically Active Ribonucleic Acid From Sources Enriched in Ribonuclease,”Biochemistry18:5294-5299 (1979).
Fischer et al., “A Ki-1 (CD30)-Positive Human Cell Line (Karpas 299) Established From a High-Grade Non-Hodgkin's Lymphoma, Showing a 2;5 Translocation and Rearrangement of the T-Cell Receptor β-Chain Gene,”Blood72:234-240 (1988).
Freeman et al., “Cloning of B7-2: A CTLA-4 Counter-Receptor That Costimulates Human T Cell Proliferation,”Science262:909-911 (1993).
Goettrup et al., “A Third Interferon-γ-Induced Subunit Exchange in the 20S Proteasome,”Eur. J. Immunol.26:863-869 (1996).
Hara et al., “Human T Cell Activation,”Journal of Experimental Medicine161:1513-1524 (1985).
Kirk et al., “CTLA4-Ig and Anti-CD40 Ligand Prevent Renal Allograft Rejection in Primates,”Proc. Natl. Acad. Sci. USA94:8789-8794 (1997).
Kroczek, “Southern and Northern Analysis,”Journal of Chromatography618:133-145 (1993).
Buonfiglio et al., 2000, “The T cell activation molecule H4 and the CD28-like molecule ICOS are identical”, Eur. J., Immunol. 30:3463-3467.
Buonfiglio et al., 1999, “Characterization of a novel human surface molecule selectively expressed by mature thymocytes, activated T cells and subsets of T cell lymphomas”, Eur. J, Immunol. 30:3463-3467.
Greenfield et al., 1998, “CD28/B7 costimulation: a review”, Crit. Rev. Immunol. 18:389-418.
Lenschow et al., 1996, “CD28/B7 system of T cell costimulation”, Annu. Rev. Immunol. 14:233-258.
Redoglia et al. 1996, “Characterization of H4: a mouse T lymphocyte activation molecule functionally associated with the CD3/T cell receptor”, Eur. J. Immunol. 26:2781-2789.
Lanier et al., “CD80 (B7) and CD86 (B70) Provide Similar Costimulatory Signals for T Cell Proliferation, Cytokine Production, and Generation of CTL1,”The Journal of Immunologypp. 97-105 (1995).
Linsley et al., Coexpression and Functional Cooperation of CTLA-4 and CD28 on Activated T Lymphocytes,Journal of Experimental Medicine176:1595-1604 (1992).
Lucas et al., “Naive CD28-Deficient T Cells Can Initiate But Not Sustain an In Vitro Antigen-Specific Immune Response,”Journal of Immunology154:5756-5768 (1995).
Milstein and Kohler, “Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity,”Nature256:495-197 (1975).
Nishioka et al., “The role of CD40-CD40 Ligand Interaction in Human T Cell-B Cell Collaboration1,”Journal of Immunology153:1027-1036 (1994).
Riley et al., “Intrinsic Resistance to T Cell Infection with HIV Type 1 Induced by CD28 Constimulation,”Journal of Immunology158:5545-5553 (1997).
Schneider eta l., “A One-Step Purification of Membrane Proteins Using a High Efficiency Immunomatrx,”The Journal of Biological Chemistry257:10766-10769 (1982).
Shahinian et al., “Differential T Cell Costimulatory Requirements in CD28-Deficient Mice,”Science261:609-609-612 (1993).
Tamatani and Tezuka, Human Cell Surface Protein, Genseq Database Accession No. W75956, Dec. 11, 1998.
Tamatani and Tezuka, Human Cell Surface Protein, Genseq Database Accession No. V53199, Dec. 11, 1998.
Vogeli and Kaytes, “Amplification, Storage, and Replicaiton of Libraries,”Methods of Enzymology152:407-415 (1987).
Wallace and Miyada, “Oligonulcleotide Probes for the Scereening of Recombinant DNA Libraries,”Methods in Enzymology152:432-442 (1987).
Westermeier , “A Guide to Methods and Applications of DNA and Protein Separations,”Electrophoresis in PracticeVCH Verlagsgesellschaft, Weinheim, (1997).
Wozney, “Using Purified Protein to Clone Its Gene,”Methods in Enzymology182:738-751 (1990).
Dianzani et al., 1999, “Characterization of human H4, a novel surface molecule selectively expressed by activated T cells and mature thymocytes”, FASEB Journal, 13(5):712.39 Abstract #712.39.
Lucia et al., 2000, “Expression of the Novel T Cell Activation Molecule hpH4 in HIV-Infected Patients: Correlation with Disease Status”, Aids Research and Human Retroviruses, 18(6):549-557.
Bundersrespublik Deutschaland Letztvertreten Durch Den Direktor
Gambel Phillip
Jones Day
Ouspenski Ilia
LandOfFree
Anti-human T-cell costimulating polypeptide monoclonal... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-human T-cell costimulating polypeptide monoclonal..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-human T-cell costimulating polypeptide monoclonal... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3888341